Source: JAMA Health Forum Repost to share with colleagues navigating GLP-1 coverage decisions Follow me for more on employer pharmacy benefits (Bryce Platt, PharmD) As with most things in healthcare spend, this is complicated, however, I would be quite surprised if more widespread availabity would not lead to substantial cost savings over time (not necessarily for the plans, as many of those savings may be later and for Medicare etc.) Prices have continued to drop from 2025 numbers and will likely continue with more competition and more users, and, as with all medicines, costs will drop quite a bit as the first generics start coming, so this is not a cost forever, it is for a few years
Patients should still discuss appropriateness, safety, and monitoring with a qualified healthcare professional before use
Contraindications: Active uveal inflammation Most cases of angle-closure glaucoma , due to the possibility of increasing angle block Hypersensitivity to the active or inactive ingredients Side Effects: Retinal detachment has been reported in a few cases Stinging, burning, lacrimation Iris cysts may form Lens opacities Cardiac irregularities Pharmacokinetics: Administered in eye drops to patients with glaucoma ) Forms an irreversible covalent bond with the ACh binding site on cholinesterase (duration of action is ~100 hrs Drug Interactions: Potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects References: Merck Manual Professional Edition (2026): Medications Used to Treat Glaucoma
For recurrent hypoglycaemia, persistent severe symptoms, or new neurological signs, contact your GP or diabetes care team promptly
For example, peptide YY and glucagon-like peptide-1 (GLP-1) are released in response to food intake and influence appetite and glucose metabolism, with receptors in the brain that affect satiety and cognitive function [43]
